カテゴリ： Allied Market Research, 世界, 医療/バイオ

出生前・新生児遺伝学的検査のグローバル市場（2021～2031）：消耗品、器具

■ 英語タイトル：Prenatal and Newborn Genetic Testing Market By Product Type (Consumables, Instruments), By Screening (Non-invasive Prenatal Testing, Chronic Villus Sampling, Amniocentesis, Maternal Serum Screening, Others), By Disease (Downs Syndrome, Phenylketonuria, Cystic Fibrosis, Sickle Cell Anemia, others), By End User (Hospital, Maternity and Specialty Clinics, Diagnostic centers): Global Opportunity Analysis and Industry Forecast, 2021-2031

調査会社Allied Market Research社が発行したリサーチレポート（データ管理コード：ALD23MC086）■ 発行会社/調査会社：Allied Market Research
■ 商品コード：ALD23MC086
■ 発行日：2023年1月
■ 調査対象地域：グローバル
■ 産業分野：医療
■ ページ数：256
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Online Only（1名閲覧、印刷不可）USD3,570 ⇒換算￥542,640見積依頼/購入/質問フォーム
Single User（1名閲覧）USD5,730 ⇒換算￥870,960見積依頼/購入/質問フォーム
Enterprise User（閲覧人数無制限）USD9,600 ⇒換算￥1,459,200見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Allied Market Research社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[出生前・新生児遺伝学的検査のグローバル市場（2021～2031）：消耗品、器具]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

Allied Market Research社の調査資料では、2021年には4,891.51百万ドルであった世界の出生前・新生児遺伝学的検査市場規模が2031年には14,727.30百万ドルへ及び、2022年から2031年の間にCAGR 11.5％増加すると推測されています。本調査資料では、出生前・新生児遺伝学的検査の世界市場を広く調査・分析し、イントロダクション、エグゼクティブサマリー、市場概要、製品種類別（消耗品、器具）分析、スクリーニング別（非侵襲的出生前検査、慢性絨毛採取、羊水穿刺、母体血清スクリーニング、その他）分析、疾患別（ダウン症、フェニルケトン尿症、嚢胞性線維症、鎌状赤血球症、その他）分析、エンドユーザー別（病院、産科・専門クリニック、診断センター）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米/中東・アフリカ）分析、競争状況、企業情報などを整理しました。並びに、本資料に記載されている企業として、Bio-Rad Laboratories, Inc.、Mettler Toledo、Thermo Fisher Scientific Inc.、Abbott Laboratories、Laboratory Corporation of America Holdings、BGI Group、PerkinElmer Inc.、Natera, Inc.、F. Hoffmann-La Roche AG、Quest Diagnostics Incorporatedなどが含まれています。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・世界の出生前・新生児遺伝学的検査市場規模：製品種類別
- 消耗品の市場規模
- 器具の市場規模
・世界の出生前・新生児遺伝学的検査市場規模：スクリーニング別
- 非侵襲的出生前検査の市場規模
- 慢性絨毛採取の市場規模
- 羊水穿刺の市場規模
- 母体血清スクリーニングの市場規模
- その他出生前・新生児遺伝学的検査の市場規模
・世界の出生前・新生児遺伝学的検査市場規模：疾患別
- ダウン症における市場規模
- フェニルケトン尿症における市場規模
- 嚢胞性線維症における市場規模
- 鎌状赤血球症における市場規模
- その他疾患における市場規模
・世界の出生前・新生児遺伝学的検査市場規模：エンドユーザー別
- 病院における市場規模
- 産科・専門クリニックにおける市場規模
- 診断センターにおける市場規模
・世界の出生前・新生児遺伝学的検査市場規模：地域別
- 北米の出生前・新生児遺伝学的検査市場規模
- ヨーロッパの出生前・新生児遺伝学的検査市場規模
- アジア太平洋の出生前・新生児遺伝学的検査市場規模
- 中南米/中東・アフリカの出生前・新生児遺伝学的検査市場規模
・競争状況
・企業情報

出生前・新生児遺伝学的検査市場は、2021年に48億9,151万ドル、2031年には147億2,730万ドルに達すると推定され、2022年から2031年までの年平均成長率は11.5%となる見込みです。
出生前検査とは、妊娠中に実施される医療検査で、妊娠に関する問題を検出するための出生前診断と出生前スクリーニングで構成されています。胎児が遺伝的疾患を持って生まれる可能性があるかどうかを判断するために、妊娠中の女性に妊娠第1期または第2期に提供されます。新生児検査は、生まれたばかりの赤ちゃんの遺伝子異常を診断するために、米国のすべての州で行われている公衆衛生サービスと考えられています。遺伝性疾患を早期に発見することで、より重篤な遺伝性異常を防ぐことができ、親が障害を持った子供を産むことを防ぐことができるのが、出生前遺伝子検査の最大の利点です。遺伝学的検査法には、ポリメラーゼ連鎖反応（PCR）、蛍光in-situハイブリダイゼーション、アレイ比較ゲノムハイブリダイゼーションなどがあります。

出生前・新生児遺伝学的検査市場の成長は、嚢胞性線維症、ダウン症候群、フェニルケトン尿症などの遺伝性疾患の発生率と有病率の上昇、出生前・新生児遺伝学的検査法の技術的進歩の上昇によってもたらされます。遺伝性疾患の有病率の増加は、疾患の診断のための出生前・新生児遺伝学的検査の高い採用を推進しています。国立医学図書館は、フェニルケトン尿症は新生児10,000人に1人の割合で発生すると推定しています。例えば、米国疾病予防管理センター（CDC）が発表したデータによると、2022年5月、鎌状赤血球症はアフリカ系アメリカ人の出生365人に1人の割合で発症しています。

さらに、技術進歩の高まりも市場成長を後押しする重要な要因です。例えば、2022年8月、F. Hoffmann-La Roche AGは、次世代デジタルPCRシステムであるDigital LightCycler Systemを発売しました。このシステムは、高感度で精密なRNAおよびDNA分析を行うために設計されています。

しかし、非侵襲的出生前検査（NIPT）やその他の診断検査にかかるコストが高いため、出生前・新生児遺伝学的検査の導入が制限され、それが市場の成長を抑制しています。例えば、慢性絨毛サンプリングは約3,050ドル、羊水穿刺は保険なしで約4,100ドルかかります。

一方、米国、カナダ、ドイツなどの先進国における医療需要の増加や新興市場における成長機会は、予測期間中、出生前・新生児遺伝学的検査市場に大きなチャンスをもたらすと期待されています。さらに、発作の診断とモニタリングのための出生前・新生児遺伝学的検査の使用に関する意識の高まりが、予測期間中の市場成長を促進すると予想されます。

出生前・新生児遺伝学的検査市場は、製品タイプ、スクリーニング、疾患、エンドユーザーに区分されます。
製品タイプ別では、市場は機器と消耗品に二分されます。
スクリーニング別では、市場は非侵襲的出生前検査（NIPT）、慢性絨毛サンプリング（CVS）、羊水穿刺、母体血清スクリーニング（MSS）、その他に分類されます。
疾患別では、ダウン症候群、フェニルケトン尿症、嚢胞性線維症、鎌状赤血球貧血、その他に分類されます。
エンドユーザー別では、市場は病院、産科・専門クリニック、診断センターに分類されます。
地域別では、北米（米国、カナダ、メキシコ）、欧州（ドイツ、フランス、英国、イタリア、スペイン、欧州のその他地域）、アジア太平洋（中国、日本、インド、オーストラリア、韓国、アジア太平洋のその他地域）、LAMEA（ブラジル、サウジアラビア、南アフリカ、LAMEAのその他地域）に市場を分けて分析しています。

世界の出生前・新生児遺伝学的検査市場で事業を展開する主な主要企業は、Bio-Rad Laboratories, Inc.、PerkinElmer Inc.、Natera, Inc.、Quest Diagnostics Incorporated、F. Hoffmann-La Roche AG、Mettler Toledo、Laboratory Corporation of America Holdings、Thermo Fisher Scientific Inc.、Abbott Laboratories、BGI Groupなどです。

〈ステークホルダーにとっての主なメリット〉
・本レポートは、2021年から2031年までの出生前・新生児遺伝学的検査市場分析の市場セグメント、現在の動向、予測、ダイナミクスを定量的に分析し、出生前・新生児遺伝学的検査市場の有力な市場機会を特定します。
・主要な促進要因、阻害要因、機会に関する情報とともに市場調査を提供します。
・ポーターのファイブフォース分析により、バイヤーとサプライヤーの潜在力を明らかにし、ステークホルダーが利益志向のビジネス決定を行い、サプライヤーとバイヤーのネットワークを強化できるようにします。
・出生前・新生児遺伝学的検査市場のセグメンテーションを詳細に分析することで、市場機会を見極めることができます。
・出生前・新生児遺伝学的検査市場の細分化に関する詳細な分析は、市場機会を決定するのに役立ちます。
・市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
・出生前・新生児遺伝学的検査の地域別および世界市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析を含みます。

〈主要市場セグメント〉
製品タイプ別
消耗品
検査機器

スクリーニング別
非侵襲的出生前検査
慢性絨毛サンプリング
羊水穿刺
母体血清スクリーニング
その他

疾患別
ダウン症
フェニルケトン尿症
嚢胞性線維症
鎌状赤血球貧血
その他

エンドユーザー別
病院
産科＆専門クリニック
診断センター

地域別
・北米
アメリカ
カナダ
メキシコ
・ヨーロッパ
ドイツ
フランス
イギリス
イタリア
スペイン
その他のヨーロッパ
・アジア太平洋
日本
中国
オーストラリア
インド
韓国
その他のアジア太平洋地域
・LAMEA
ブラジル
サウジアラビア
南アフリカ
その他のLAMEA地域

〈主要市場プレイヤー〉
Bio-Rad Laboratories, Inc.
Mettler Toledo
Thermo Fisher Scientific Inc.
Abbott Laboratories
Laboratory Corporation of America Holdings
BGI Group
PerkinElmer Inc.
Natera, Inc.
F. Hoffmann-La Roche AG
Quest Diagnostics Incorporated

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Moderate bargaining power of suppliers
3.3.2. Moderate bargaining power of buyers
3.3.3. Moderate threat of substitutes
3.3.4. High threat of new entrants
3.3.5. Moderate intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increase in prevalence of genetic diseases among infants
3.4.1.2. Rise in demand for non-invasive prenatal testing

3.4.2. Restraints
3.4.2.1. High cost of complex prenatal and newborn genetic testing

3.4.3. Opportunities
3.4.3.1. Lucrative growth opportunities in developing countries

3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY PRODUCT TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Consumables
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Instruments
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
CHAPTER 5: PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY SCREENING
5.1. Overview
5.1.1. Market size and forecast
5.2. Non-invasive Prenatal Testing
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Chronic Villus Sampling
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Amniocentesis
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Maternal Serum Screening
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
5.6. Others
5.6.1. Key market trends, growth factors and opportunities
5.6.2. Market size and forecast, by region
5.6.3. Market share analysis by country
CHAPTER 6: PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY DISEASE
6.1. Overview
6.1.1. Market size and forecast
6.2. Downs Syndrome
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Phenylketonuria
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Cystic Fibrosis
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
6.5. Sickle Cell Anemia
6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast, by region
6.5.3. Market share analysis by country
6.6. others
6.6.1. Key market trends, growth factors and opportunities
6.6.2. Market size and forecast, by region
6.6.3. Market share analysis by country
CHAPTER 7: PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY END USER
7.1. Overview
7.1.1. Market size and forecast
7.2. Hospital
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by region
7.2.3. Market share analysis by country
7.3. Maternity and Specialty Clinics
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by region
7.3.3. Market share analysis by country
7.4. Diagnostic centers
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by region
7.4.3. Market share analysis by country
CHAPTER 8: PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY REGION
8.1. Overview
8.1.1. Market size and forecast By Region
8.2. North America
8.2.1. Key trends and opportunities
8.2.2. Market size and forecast, by Product Type
8.2.3. Market size and forecast, by Screening
8.2.4. Market size and forecast, by Disease
8.2.5. Market size and forecast, by End User
8.2.6. Market size and forecast, by country
8.2.6.1. U.S.
8.2.6.1.1. Key market trends, growth factors and opportunities
8.2.6.1.2. Market size and forecast, by Product Type
8.2.6.1.3. Market size and forecast, by Screening
8.2.6.1.4. Market size and forecast, by Disease
8.2.6.1.5. Market size and forecast, by End User
8.2.6.2. Canada
8.2.6.2.1. Key market trends, growth factors and opportunities
8.2.6.2.2. Market size and forecast, by Product Type
8.2.6.2.3. Market size and forecast, by Screening
8.2.6.2.4. Market size and forecast, by Disease
8.2.6.2.5. Market size and forecast, by End User
8.2.6.3. Mexico
8.2.6.3.1. Key market trends, growth factors and opportunities
8.2.6.3.2. Market size and forecast, by Product Type
8.2.6.3.3. Market size and forecast, by Screening
8.2.6.3.4. Market size and forecast, by Disease
8.2.6.3.5. Market size and forecast, by End User
8.3. Europe
8.3.1. Key trends and opportunities
8.3.2. Market size and forecast, by Product Type
8.3.3. Market size and forecast, by Screening
8.3.4. Market size and forecast, by Disease
8.3.5. Market size and forecast, by End User
8.3.6. Market size and forecast, by country
8.3.6.1. Germany
8.3.6.1.1. Key market trends, growth factors and opportunities
8.3.6.1.2. Market size and forecast, by Product Type
8.3.6.1.3. Market size and forecast, by Screening
8.3.6.1.4. Market size and forecast, by Disease
8.3.6.1.5. Market size and forecast, by End User
8.3.6.2. France
8.3.6.2.1. Key market trends, growth factors and opportunities
8.3.6.2.2. Market size and forecast, by Product Type
8.3.6.2.3. Market size and forecast, by Screening
8.3.6.2.4. Market size and forecast, by Disease
8.3.6.2.5. Market size and forecast, by End User
8.3.6.3. UK
8.3.6.3.1. Key market trends, growth factors and opportunities
8.3.6.3.2. Market size and forecast, by Product Type
8.3.6.3.3. Market size and forecast, by Screening
8.3.6.3.4. Market size and forecast, by Disease
8.3.6.3.5. Market size and forecast, by End User
8.3.6.4. Italy
8.3.6.4.1. Key market trends, growth factors and opportunities
8.3.6.4.2. Market size and forecast, by Product Type
8.3.6.4.3. Market size and forecast, by Screening
8.3.6.4.4. Market size and forecast, by Disease
8.3.6.4.5. Market size and forecast, by End User
8.3.6.5. Spain
8.3.6.5.1. Key market trends, growth factors and opportunities
8.3.6.5.2. Market size and forecast, by Product Type
8.3.6.5.3. Market size and forecast, by Screening
8.3.6.5.4. Market size and forecast, by Disease
8.3.6.5.5. Market size and forecast, by End User
8.3.6.6. Rest of Europe
8.3.6.6.1. Key market trends, growth factors and opportunities
8.3.6.6.2. Market size and forecast, by Product Type
8.3.6.6.3. Market size and forecast, by Screening
8.3.6.6.4. Market size and forecast, by Disease
8.3.6.6.5. Market size and forecast, by End User
8.4. Asia-Pacific
8.4.1. Key trends and opportunities
8.4.2. Market size and forecast, by Product Type
8.4.3. Market size and forecast, by Screening
8.4.4. Market size and forecast, by Disease
8.4.5. Market size and forecast, by End User
8.4.6. Market size and forecast, by country
8.4.6.1. Japan
8.4.6.1.1. Key market trends, growth factors and opportunities
8.4.6.1.2. Market size and forecast, by Product Type
8.4.6.1.3. Market size and forecast, by Screening
8.4.6.1.4. Market size and forecast, by Disease
8.4.6.1.5. Market size and forecast, by End User
8.4.6.2. China
8.4.6.2.1. Key market trends, growth factors and opportunities
8.4.6.2.2. Market size and forecast, by Product Type
8.4.6.2.3. Market size and forecast, by Screening
8.4.6.2.4. Market size and forecast, by Disease
8.4.6.2.5. Market size and forecast, by End User
8.4.6.3. Australia
8.4.6.3.1. Key market trends, growth factors and opportunities
8.4.6.3.2. Market size and forecast, by Product Type
8.4.6.3.3. Market size and forecast, by Screening
8.4.6.3.4. Market size and forecast, by Disease
8.4.6.3.5. Market size and forecast, by End User
8.4.6.4. India
8.4.6.4.1. Key market trends, growth factors and opportunities
8.4.6.4.2. Market size and forecast, by Product Type
8.4.6.4.3. Market size and forecast, by Screening
8.4.6.4.4. Market size and forecast, by Disease
8.4.6.4.5. Market size and forecast, by End User
8.4.6.5. South Korea
8.4.6.5.1. Key market trends, growth factors and opportunities
8.4.6.5.2. Market size and forecast, by Product Type
8.4.6.5.3. Market size and forecast, by Screening
8.4.6.5.4. Market size and forecast, by Disease
8.4.6.5.5. Market size and forecast, by End User
8.4.6.6. Rest of Asia-Pacific
8.4.6.6.1. Key market trends, growth factors and opportunities
8.4.6.6.2. Market size and forecast, by Product Type
8.4.6.6.3. Market size and forecast, by Screening
8.4.6.6.4. Market size and forecast, by Disease
8.4.6.6.5. Market size and forecast, by End User
8.5. LAMEA
8.5.1. Key trends and opportunities
8.5.2. Market size and forecast, by Product Type
8.5.3. Market size and forecast, by Screening
8.5.4. Market size and forecast, by Disease
8.5.5. Market size and forecast, by End User
8.5.6. Market size and forecast, by country
8.5.6.1. Brazil
8.5.6.1.1. Key market trends, growth factors and opportunities
8.5.6.1.2. Market size and forecast, by Product Type
8.5.6.1.3. Market size and forecast, by Screening
8.5.6.1.4. Market size and forecast, by Disease
8.5.6.1.5. Market size and forecast, by End User
8.5.6.2. Saudi Arabia
8.5.6.2.1. Key market trends, growth factors and opportunities
8.5.6.2.2. Market size and forecast, by Product Type
8.5.6.2.3. Market size and forecast, by Screening
8.5.6.2.4. Market size and forecast, by Disease
8.5.6.2.5. Market size and forecast, by End User
8.5.6.3. South Africa
8.5.6.3.1. Key market trends, growth factors and opportunities
8.5.6.3.2. Market size and forecast, by Product Type
8.5.6.3.3. Market size and forecast, by Screening
8.5.6.3.4. Market size and forecast, by Disease
8.5.6.3.5. Market size and forecast, by End User
8.5.6.4. Rest of LAMEA
8.5.6.4.1. Key market trends, growth factors and opportunities
8.5.6.4.2. Market size and forecast, by Product Type
8.5.6.4.3. Market size and forecast, by Screening
8.5.6.4.4. Market size and forecast, by Disease
8.5.6.4.5. Market size and forecast, by End User
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Top player positioning, 2021
CHAPTER 10: COMPANY PROFILES
10.1. Bio-Rad Laboratories, Inc.
10.1.1. Company overview
10.1.2. Key Executives
10.1.3. Company snapshot
10.1.4. Operating business segments
10.1.5. Product portfolio
10.1.6. Business performance
10.2. PerkinElmer Inc.
10.2.1. Company overview
10.2.2. Key Executives
10.2.3. Company snapshot
10.2.4. Operating business segments
10.2.5. Product portfolio
10.2.6. Business performance
10.2.7. Key strategic moves and developments
10.3. Natera, Inc.
10.3.1. Company overview
10.3.2. Key Executives
10.3.3. Company snapshot
10.3.4. Operating business segments
10.3.5. Product portfolio
10.3.6. Business performance
10.4. Quest Diagnostics Incorporated
10.4.1. Company overview
10.4.2. Key Executives
10.4.3. Company snapshot
10.4.4. Operating business segments
10.4.5. Product portfolio
10.4.6. Business performance
10.5. F. Hoffmann-La Roche AG
10.5.1. Company overview
10.5.2. Key Executives
10.5.3. Company snapshot
10.5.4. Operating business segments
10.5.5. Product portfolio
10.5.6. Business performance
10.5.7. Key strategic moves and developments
10.6. Mettler Toledo
10.6.1. Company overview
10.6.2. Key Executives
10.6.3. Company snapshot
10.6.4. Operating business segments
10.6.5. Product portfolio
10.6.6. Business performance
10.7. Laboratory Corporation of America Holdings
10.7.1. Company overview
10.7.2. Key Executives
10.7.3. Company snapshot
10.7.4. Operating business segments
10.7.5. Product portfolio
10.7.6. Business performance
10.8. Thermo Fisher Scientific Inc.
10.8.1. Company overview
10.8.2. Key Executives
10.8.3. Company snapshot
10.8.4. Operating business segments
10.8.5. Product portfolio
10.8.6. Business performance
10.9. Abbott Laboratories
10.9.1. Company overview
10.9.2. Key Executives
10.9.3. Company snapshot
10.9.4. Operating business segments
10.9.5. Product portfolio
10.9.6. Business performance
10.10. BGI Group
10.10.1. Company overview
10.10.2. Key Executives
10.10.3. Company snapshot
10.10.4. Operating business segments
10.10.5. Product portfolio

LIST OF TABLES
TABLE 01. GLOBAL PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 02. PRENATAL AND NEWBORN GENETIC TESTING MARKET FOR CONSUMABLES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 03. PRENATAL AND NEWBORN GENETIC TESTING MARKET FOR INSTRUMENTS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 04. GLOBAL PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY SCREENING, 2021-2031 (REVENUE, $MILLION)
TABLE 05. PRENATAL AND NEWBORN GENETIC TESTING MARKET FOR NON-INVASIVE PRENATAL TESTING, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 06. PRENATAL AND NEWBORN GENETIC TESTING MARKET FOR CHRONIC VILLUS SAMPLING, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 07. PRENATAL AND NEWBORN GENETIC TESTING MARKET FOR AMNIOCENTESIS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 08. PRENATAL AND NEWBORN GENETIC TESTING MARKET FOR MATERNAL SERUM SCREENING, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 09. PRENATAL AND NEWBORN GENETIC TESTING MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 10. GLOBAL PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY DISEASE, 2021-2031 (REVENUE, $MILLION)
TABLE 11. PRENATAL AND NEWBORN GENETIC TESTING MARKET FOR DOWNS SYNDROME, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 12. PRENATAL AND NEWBORN GENETIC TESTING MARKET FOR PHENYLKETONURIA, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 13. PRENATAL AND NEWBORN GENETIC TESTING MARKET FOR CYSTIC FIBROSIS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 14. PRENATAL AND NEWBORN GENETIC TESTING MARKET FOR SICKLE CELL ANEMIA, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 15. PRENATAL AND NEWBORN GENETIC TESTING MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 16. GLOBAL PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 17. PRENATAL AND NEWBORN GENETIC TESTING MARKET FOR HOSPITAL, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 18. PRENATAL AND NEWBORN GENETIC TESTING MARKET FOR MATERNITY AND SPECIALTY CLINICS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 19. PRENATAL AND NEWBORN GENETIC TESTING MARKET FOR DIAGNOSTIC CENTERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 20. PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 21. NORTH AMERICA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 22. NORTH AMERICA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY SCREENING, 2021-2031 (REVENUE, $MILLION)
TABLE 23. NORTH AMERICA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY DISEASE, 2021-2031 (REVENUE, $MILLION)
TABLE 24. NORTH AMERICA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 25. NORTH AMERICA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 26. U.S. PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 27. U.S. PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY SCREENING, 2021-2031 (REVENUE, $MILLION)
TABLE 28. U.S. PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY DISEASE, 2021-2031 (REVENUE, $MILLION)
TABLE 29. U.S. PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 30. CANADA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 31. CANADA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY SCREENING, 2021-2031 (REVENUE, $MILLION)
TABLE 32. CANADA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY DISEASE, 2021-2031 (REVENUE, $MILLION)
TABLE 33. CANADA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 34. MEXICO PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 35. MEXICO PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY SCREENING, 2021-2031 (REVENUE, $MILLION)
TABLE 36. MEXICO PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY DISEASE, 2021-2031 (REVENUE, $MILLION)
TABLE 37. MEXICO PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 38. EUROPE PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 39. EUROPE PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY SCREENING, 2021-2031 (REVENUE, $MILLION)
TABLE 40. EUROPE PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY DISEASE, 2021-2031 (REVENUE, $MILLION)
TABLE 41. EUROPE PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 42. EUROPE PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 43. GERMANY PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 44. GERMANY PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY SCREENING, 2021-2031 (REVENUE, $MILLION)
TABLE 45. GERMANY PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY DISEASE, 2021-2031 (REVENUE, $MILLION)
TABLE 46. GERMANY PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 47. FRANCE PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 48. FRANCE PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY SCREENING, 2021-2031 (REVENUE, $MILLION)
TABLE 49. FRANCE PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY DISEASE, 2021-2031 (REVENUE, $MILLION)
TABLE 50. FRANCE PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 51. UK PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 52. UK PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY SCREENING, 2021-2031 (REVENUE, $MILLION)
TABLE 53. UK PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY DISEASE, 2021-2031 (REVENUE, $MILLION)
TABLE 54. UK PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 55. ITALY PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 56. ITALY PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY SCREENING, 2021-2031 (REVENUE, $MILLION)
TABLE 57. ITALY PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY DISEASE, 2021-2031 (REVENUE, $MILLION)
TABLE 58. ITALY PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 59. SPAIN PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 60. SPAIN PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY SCREENING, 2021-2031 (REVENUE, $MILLION)
TABLE 61. SPAIN PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY DISEASE, 2021-2031 (REVENUE, $MILLION)
TABLE 62. SPAIN PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 63. REST OF EUROPE PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 64. REST OF EUROPE PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY SCREENING, 2021-2031 (REVENUE, $MILLION)
TABLE 65. REST OF EUROPE PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY DISEASE, 2021-2031 (REVENUE, $MILLION)
TABLE 66. REST OF EUROPE PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 67. ASIA-PACIFIC PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 68. ASIA-PACIFIC PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY SCREENING, 2021-2031 (REVENUE, $MILLION)
TABLE 69. ASIA-PACIFIC PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY DISEASE, 2021-2031 (REVENUE, $MILLION)
TABLE 70. ASIA-PACIFIC PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 71. ASIA-PACIFIC PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 72. JAPAN PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 73. JAPAN PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY SCREENING, 2021-2031 (REVENUE, $MILLION)
TABLE 74. JAPAN PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY DISEASE, 2021-2031 (REVENUE, $MILLION)
TABLE 75. JAPAN PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 76. CHINA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 77. CHINA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY SCREENING, 2021-2031 (REVENUE, $MILLION)
TABLE 78. CHINA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY DISEASE, 2021-2031 (REVENUE, $MILLION)
TABLE 79. CHINA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 80. AUSTRALIA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 81. AUSTRALIA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY SCREENING, 2021-2031 (REVENUE, $MILLION)
TABLE 82. AUSTRALIA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY DISEASE, 2021-2031 (REVENUE, $MILLION)
TABLE 83. AUSTRALIA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 84. INDIA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 85. INDIA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY SCREENING, 2021-2031 (REVENUE, $MILLION)
TABLE 86. INDIA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY DISEASE, 2021-2031 (REVENUE, $MILLION)
TABLE 87. INDIA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 88. SOUTH KOREA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 89. SOUTH KOREA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY SCREENING, 2021-2031 (REVENUE, $MILLION)
TABLE 90. SOUTH KOREA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY DISEASE, 2021-2031 (REVENUE, $MILLION)
TABLE 91. SOUTH KOREA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 92. REST OF ASIA-PACIFIC PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 93. REST OF ASIA-PACIFIC PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY SCREENING, 2021-2031 (REVENUE, $MILLION)
TABLE 94. REST OF ASIA-PACIFIC PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY DISEASE, 2021-2031 (REVENUE, $MILLION)
TABLE 95. REST OF ASIA-PACIFIC PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 96. LAMEA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 97. LAMEA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY SCREENING, 2021-2031 (REVENUE, $MILLION)
TABLE 98. LAMEA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY DISEASE, 2021-2031 (REVENUE, $MILLION)
TABLE 99. LAMEA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 100. LAMEA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 101. BRAZIL PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 102. BRAZIL PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY SCREENING, 2021-2031 (REVENUE, $MILLION)
TABLE 103. BRAZIL PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY DISEASE, 2021-2031 (REVENUE, $MILLION)
TABLE 104. BRAZIL PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 105. SAUDI ARABIA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 106. SAUDI ARABIA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY SCREENING, 2021-2031 (REVENUE, $MILLION)
TABLE 107. SAUDI ARABIA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY DISEASE, 2021-2031 (REVENUE, $MILLION)
TABLE 108. SAUDI ARABIA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 109. SOUTH AFRICA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 110. SOUTH AFRICA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY SCREENING, 2021-2031 (REVENUE, $MILLION)
TABLE 111. SOUTH AFRICA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY DISEASE, 2021-2031 (REVENUE, $MILLION)
TABLE 112. SOUTH AFRICA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 113. REST OF LAMEA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 114. REST OF LAMEA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY SCREENING, 2021-2031 (REVENUE, $MILLION)
TABLE 115. REST OF LAMEA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY DISEASE, 2021-2031 (REVENUE, $MILLION)
TABLE 116. REST OF LAMEA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 117. BIO-RAD LABORATORIES, INC.: KEY EXECUTIVES
TABLE 118. BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
TABLE 119. BIO-RAD LABORATORIES, INC.: PRODUCT SEGMENTS
TABLE 120. BIO-RAD LABORATORIES, INC.: PRODUCT PORTFOLIO
TABLE 121. PERKINELMER INC.: KEY EXECUTIVES
TABLE 122. PERKINELMER INC.: COMPANY SNAPSHOT
TABLE 123. PERKINELMER INC.: PRODUCT SEGMENTS
TABLE 124. PERKINELMER INC.: PRODUCT PORTFOLIO
TABLE 125. PERKINELMER INC.: KEY STRATERGIES
TABLE 126. NATERA, INC.: KEY EXECUTIVES
TABLE 127. NATERA, INC.: COMPANY SNAPSHOT
TABLE 128. NATERA, INC.: PRODUCT SEGMENTS
TABLE 129. NATERA, INC.: PRODUCT PORTFOLIO
TABLE 130. QUEST DIAGNOSTICS INCORPORATED: KEY EXECUTIVES
TABLE 131. QUEST DIAGNOSTICS INCORPORATED: COMPANY SNAPSHOT
TABLE 132. QUEST DIAGNOSTICS INCORPORATED: PRODUCT SEGMENTS
TABLE 133. QUEST DIAGNOSTICS INCORPORATED: PRODUCT PORTFOLIO
TABLE 134. F. HOFFMANN-LA ROCHE AG: KEY EXECUTIVES
TABLE 135. F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT
TABLE 136. F. HOFFMANN-LA ROCHE AG: PRODUCT SEGMENTS
TABLE 137. F. HOFFMANN-LA ROCHE AG: PRODUCT PORTFOLIO
TABLE 138. F. HOFFMANN-LA ROCHE AG: KEY STRATERGIES
TABLE 139. METTLER TOLEDO: KEY EXECUTIVES
TABLE 140. METTLER TOLEDO: COMPANY SNAPSHOT
TABLE 141. METTLER TOLEDO: PRODUCT SEGMENTS
TABLE 142. METTLER TOLEDO: PRODUCT PORTFOLIO
TABLE 143. LABORATORY CORPORATION OF AMERICA HOLDINGS: KEY EXECUTIVES
TABLE 144. LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT
TABLE 145. LABORATORY CORPORATION OF AMERICA HOLDINGS: PRODUCT SEGMENTS
TABLE 146. LABORATORY CORPORATION OF AMERICA HOLDINGS: PRODUCT PORTFOLIO
TABLE 147. THERMO FISHER SCIENTIFIC INC.: KEY EXECUTIVES
TABLE 148. THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
TABLE 149. THERMO FISHER SCIENTIFIC INC.: PRODUCT SEGMENTS
TABLE 150. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
TABLE 151. ABBOTT LABORATORIES: KEY EXECUTIVES
TABLE 152. ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 153. ABBOTT LABORATORIES: PRODUCT SEGMENTS
TABLE 154. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 155. BGI GROUP: KEY EXECUTIVES
TABLE 156. BGI GROUP: COMPANY SNAPSHOT
TABLE 157. BGI GROUP: PRODUCT SEGMENTS
TABLE 158. BGI GROUP: PRODUCT PORTFOLIO

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • キャリアスクリーニングのグローバル市場（2021〜2031）：拡張キャリアスクリーニング、標的疾患キャリアスクリーニング
  • 角膜インプラントのグローバル市場（2021-2031）：全層角膜形成術、内皮角膜移植術、その他
  • 肺がんスクリーニングのグローバル市場（2021〜2031）：低線量コンピューター断層撮影（LDCT）、X線
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(ALD23MC086 )"出生前・新生児遺伝学的検査のグローバル市場（2021～2031）：消耗品、器具" (英文：Prenatal and Newborn Genetic Testing Market By Product Type (Consumables, Instruments), By Screening (Non-invasive Prenatal Testing, Chronic Villus Sampling, Amniocentesis, Maternal Serum Screening, Others), By Disease (Downs Syndrome, Phenylketonuria, Cystic Fibrosis, Sickle Cell Anemia, others), By End User (Hospital, Maternity and Specialty Clinics, Diagnostic centers): Global Opportunity Analysis and Industry Forecast, 2021-2031)はAllied Market Research社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。